文献速递妇科

尼达尼布治疗贝伐珠单抗耐药复发性上皮性卵巢癌、输卵管癌和腹膜癌的II期试验

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
PubMed 文献 · Gynecol Oncol · 2019-03-28

这项II期试验评估尼达尼布200 mg/天治疗贝伐珠单抗耐药复发性上皮性卵巢癌、输卵管癌和腹膜癌,主要终点6个月无进展生存率为11.5%(3/26),中位无进展生存期1.8个月,中位总生存期16个月,缓解率7.4%(2/27部分缓解),单药活性有限但毒性可管理。

要点

  • 尼达尼布200 mg/天在贝伐珠单抗耐药复发性EOC中6个月PFS率为11.5%(3/26)。
  • 缓解率7.4%(2/27 PR),37%(10/27)疾病稳定,56%(15/27)疾病进展。
  • 血浆CD73、IL6、VEGFD与疾病进展相关,IL6与更差PFS相关(p=0.03)。

核心结论

  • 单药尼达尼布在未选择的贝伐珠单抗耐药EOC人群中活性有限,但可耐受且毒性可管理。
  • 血浆CD73、IL6和VEGFD被确定为疾病进展的预后标志物,IL6与更差PFS相关。

研究设计与样本

  • II期试验,采用Simon两阶段最优设计,评估尼达尼布200 mg/天至疾病进展或不可接受毒性。
  • 27例入组可评估PFS,26例可评估6个月PFS;中位年龄65岁(范围44-73)。
  • 89.9%为高级别浆液性EOC,70%接受过至少>2线既往化疗,81%(22/27)为化疗耐药疾病。

主要发现

  • 中位随访15.6个月(范围2-38),6个月PFS率为11.5%(3/26),3例疾病控制持续8-16个月。
  • 中位PFS和总生存期分别为1.8个月和16个月,缓解率7.4%(2/27 PR)。
  • 37%(10/27)疾病稳定,56%(15/27)疾病进展。
  • 不良事件包括3级肝酶升高(15%)、3级腹泻(7%)、2级疲乏(7%)、2级恶心/呕吐(15%)。
  • 疾病进展患者CD73、IL6和VEGFD水平高于PR/SD患者(p<0.05),IL6与更差PFS相关(p=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bevacizumab provides benefit in epithelial ovarian cancer (EOC), yet resistance to bevacizumab often occurs. We determined if nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors has antitumor activity in bevacizumab-resistant recurrent EOC, tubal, and peritoneal cancer. METHODS: This phase II study evaluated nintedanib 200 mg/day until disease progression or unacceptable toxicity. The primary objective was 6-month progression free survival (PFS6m). Secondary objectives were response rate and toxicity. Simon two-stage optimal design was used. Baseline angiogenic plasma biomarkers were measured. RESULTS: 27 patients were enrolled evaluable for PFS; 26 were evaluable for PFS6m. The median age was 65 years (range 44-73); 89.9% had high-grade serous EOC; 70% received at least >2 prior chemotherapies; and 81% (22/27) had chemoresistant disease. With median follow up of 15.6 months (range 2-38) the PFS6m rate was 11.5% (3/26). Three participants had long duration of disease control (8-16 months). Median PFS and overall survival were 1.8 and 16 months, respectively. Response rate was 7.4% (2/27 PR). Thirty-seven percent (10/27) had stable disease, while 56% (15/27) had progressive disease. Adverse events included Grade 3 liver enzyme elevation (15%), Grade 3 diarrhea (7%), Grade 2 fatigue (7%), and Grade 2 nausea/vomiting (15%). PD patients exhibited higher levels of CD73, IL6, and VEGFD (p < 0.05) compared to PR/SD patients. IL6 was associated with worse PFS (p = 0.03). CONCLUSIONS: Single-agent nintedanib has minimal activity in an unselected bevacizumab-resistant EOC population. Nintedanib was tolerable and toxicities were manageable. Plasma CD73, IL6, and VEGFD were identified as prognostic markers for progressive disease, and IL6 was associated with worse PFS confirming similar observations made in patients treated with other anti-angiogenic agents.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Secord AA, McCollum M, Davidson BA, et al. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecol Oncol. 2019. PMID: 30929823. doi:10.1016/j.ygyno.2019.03.246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。